Article Link: Baxter Announces U.S FDA Approval of Myxredlin, the First and Only Ready-To-Use Insulin for IV Infusion DEERFIELD, Ill. ...
FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
Article Link: FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease SUMMIT, N.J.–(BUSI...
FDA Approves Recarbrio (imipenem, cilastatin, and relebactam) for the Treatment of Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections
Article Link: FDA Approves Recarbrio (imipenem, cilastatin, and relebactam) for the Treatment of Complicated Urinary Tract and Complicated Intra-Abdom...
FDA Approves AirDuo Digihaler (fluticasone propionate and salmeterol) Inhalation Powder for Asthma
Article Link: FDA Approves AirDuo Digihaler (fluticasone propionate and salmeterol) Inhalation Powder for Asthma JERUSALEM and PARSIPPANY...
FDA Approves Gadavist (gadobutrol) Contrast Agent for Use in Cardiac MR in Adult Patients with Known or Suspected Coronary Artery Disease
Article Link: FDA Approves Gadavist (gadobutrol) Contrast Agent for Use in Cardiac MR in Adult Patients with Known or Suspected Coronary Artery Diseas...
FDA Approves Katerzia (amlodipine) Oral Suspension for Pediatric Patients 6 Years of Age and Older
Article Link: FDA Approves Katerzia (amlodipine) Oral Suspension for Pediatric Patients 6 Years of Age and Older WOBURN, Mass. (July 10, ...
FDA Approves Xembify (immune globulin subcutaneous) for Primary Immunodeficiencies
Article Link: FDA Approves Xembify (immune globulin subcutaneous) for Primary Immunodeficiencies Barcelona, July 4, 2019.- Grifols, a lea...
FDA Approves Xpovio (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Article Link: FDA Approves Xpovio (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma NEWTON, Mass., J...
FDA Approves Thiola EC (tiopronin) for the Treatment of Cystinuria
Article Link: FDA Approves Thiola EC (tiopronin) for the Treatment of Cystinuria SAN DIEGO, June 28, 2019 (GLOBE NEWSWIRE) — Retrop...
FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin
Article Link: FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin Friday, June 28, 2019 – Pfizer Inc. (NYSE:PFE) today...
